Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc. (“Amarantus”) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death). 

The Company’s lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor, or  MANF is a targeted therapeutic to address the underlying Programmed Cell Death (Apoptosis) associated with a wide range of devastating human disorders. The Company's lead diagnostic program, NuroPro®, is aimed at developing diagnostic blood tests that are capable of early identification of apoptosis-related medical conditions while tracking their progression over time. Both programs will initially target Parkinson's disease.

Amarantus’ Management Team and Board of Advisors have designed a business strategy to formulate and advance pre-clinical and clinical programs for the Company's product candidates through successive de-risking milestones in order to maximize their commercial potential. The Company is also focused on making the assets attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies.